Related Experiment Videos
Growth inhibition by dominant-negative mutations of the neu-encoded oncoprotein
J Schlegel1, T Trenkle, G Stumm
1Department of Neuropathology, University of Marburg, Germany. Schlegel@mailer.uni-marburg.de
Abstract:
In the present study, kinase-deficient mutants of the neu gene were constructed in order to generate dominant-negative receptor molecules, which should abolish phosphorylation of receptor complexes. One construct carried a mutation of the putative ATP-binding site (K758M), while the other mutant was generated by deletion of the kinase domain (ID400). Neither receptor showed phosphorylation by in vitro kinase assay. When NIH3T3 fibroblasts were co-transfected by the oncogenic neu gene and one of either construct, the transforming effect could be partially reversed. Therefore, kinase-negative mutations of the neu-encoded receptor seemed to have a dominant-negative effect on the action of the activated protein. To test this hypothesis, rat neurinoma cell lines containing oncogenic neu genes were transfected with the constructs. Expression of the kinase-defective mutants and reduced phosphorylation could be detected in different clones derived from single transfected cells. Striking growth inhibition and reduction of colony formation in soft agar were observed in these cell lines when compared with untransfected cells. Thus, kinase-deficient mutants exert a dominant-negative effect on phosphorylation of receptor complexes, resulting in a reversion of the transformed phenotype.
Insights
Kinase-deficient neu receptor mutants were created to block receptor phosphorylation. These mutants demonstrated a dominant-negative effect, inhibiting cancer cell growth and reversing the transformed phenotype.
Area of Science:
- Molecular Biology
- Oncology
- Cell Signaling
Background:
- The neu gene encodes a receptor tyrosine kinase implicated in various cancers.
- Activating mutations in the neu gene lead to uncontrolled cell proliferation and transformation.
- Targeting receptor kinase activity is a key strategy in cancer therapy.
Purpose of the Study:
- To generate kinase-deficient neu receptor mutants.
- To investigate the dominant-negative potential of these mutants on oncogenic neu signaling.
- To assess the therapeutic implications of inhibiting neu receptor phosphorylation.
Main Methods:
- Construction of kinase-deficient neu mutants (K758M and ID400).
- In vitro kinase assays to confirm lack of phosphorylation.
- Co-transfection studies in NIH3T3 fibroblasts and rat neurinoma cell lines.
- Assessment of cell proliferation, colony formation, and receptor phosphorylation levels.
Main Results:
- Kinase-deficient neu mutants (K758M, ID400) showed no autophosphorylation.
- Co-transfection partially reversed the transforming effect of oncogenic neu in NIH3T3 cells.
- Transfection of neurinoma cells with mutants led to reduced receptor phosphorylation.
- Significant growth inhibition and decreased soft agar colony formation were observed in transfected cell lines.
Conclusions:
- Kinase-deficient neu mutants function as dominant-negative inhibitors of oncogenic neu signaling.
- Inhibition of neu receptor phosphorylation effectively reverts the transformed phenotype.
- These findings support the development of targeted therapies against neu-driven cancers.